AKAN Rallies 37% on 100:1 Reverse Split Approval and New Share Issuances

Introduction

AKANDA CORP (NASDAQ: AKAN; name in Korean: 어캔다) is a London-headquartered company specializing in the cultivation, manufacturing, and international distribution of medical cannabis and wellness products. As of December 5, 2025, its shares closed at $1.30, reflecting a 37.41% increase on that day, with a trading volume of 9,307,581 on the NASDAQ Small Cap market.

Corporate Structure

Founded to serve legal cannabis markets, Akanda operates three reportable segments: Cultivation, Distribution, and Corporate. The company employs between 201 and 500 staff across its global operations. Its cultivation segment is developing a medical-grade facility in Portugal, where non-irradiated flower production is overseen by an experienced team. Akanda has a genetics and retail partnership with Cookies, and anticipates launching Cookies-branded flower later in 2025. The Distribution segment focuses on medical cannabis oil and flower, particularly in the United Kingdom, while Corporate manages strategy, compliance, and investor relations.

Medical cannabis by Budding .

Developments and News

• October 10, 2025: Akanda announced that a postal strike in Canada delayed the delivery of proxy materials for its special shareholder meeting originally set for October 30, 2025.
• November 28, 2025: Shareholders convened an adjourned special meeting to vote on three proposals related to capital restructuring.
• December 2, 2025: The company filed a Form 6-K disclosing that shareholders approved:
  • A share consolidation (reverse split) of up to 100 old shares for 1 new share, aimed at adjusting the trading price per share.
  • Issuance of 4,775,972 Class A common shares to satisfy obligations tied to Class B Special Shares from a prior acquisition.
  • Issuance of shares for the settlement of debt under existing debt settlement agreements.

Financial and Strategic Analysis

At the close of November 2025, Akanda’s trailing twelve-month revenue stood at USD 836,660, while net income reported a loss of USD 2.4 million, resulting in a profit margin of -266.31%. Key metrics include:

• Market Capitalization: USD 713,800
• Enterprise Value: -USD 1,420,000
• P/E (TTM): 0.04
• EPS (TTM): 30.97
• Price/Sales (TTM): 0.49
• Price/Book (MRQ): 0.22
• Total Cash (MRQ): USD 2.52 million
• Total Debt/Equity (MRQ): 11.85%
  These figures reflect a small-cap structure with substantial cash relative to debt but ongoing operating losses. The approved share consolidation and issuance proposals aim to streamline capital structure, comply with NASDAQ rules, and settle obligations.

Market Position and Industry Context

Akanda competes within the global medical cannabis market, characterized by evolving regulations and rising demand for medicinal-grade products. Its partnership with Cookies secures premium genetics, and its Portuguese facility targets European and other international markets. Distribution partnerships, including digital pain clinics and prescribing doctors, facilitate patient access in legal jurisdictions. Akanda’s integrated model—combining cultivation, manufacturing, and distribution—aligns with industry trends favoring vertically integrated operators.

tl;dr

On December 5, 2025, AKAN shares increased by 37.41% to USD 1.30 amid a trading volume exceeding 9 million. On December 2, Akanda filed a Form 6-K reporting shareholder approval of a potential reverse split (up to 100:1), issuance of 4.78 million new shares tied to prior acquisition obligations, and additional share issuances to settle debt. These measures are intended to meet NASDAQ listing requirements and address capital-structure needs. Key future developments include the anticipated launch of Cookies-branded flower from its Portuguese facility and expansion of its medical cannabis distribution network.